CA3242974A1 - LIPID AND COMPOSITION USED FOR ADMINISTRATION - Google Patents
LIPID AND COMPOSITION USED FOR ADMINISTRATIONInfo
- Publication number
- CA3242974A1 CA3242974A1 CA3242974A CA3242974A CA3242974A1 CA 3242974 A1 CA3242974 A1 CA 3242974A1 CA 3242974 A CA3242974 A CA 3242974A CA 3242974 A CA3242974 A CA 3242974A CA 3242974 A1 CA3242974 A1 CA 3242974A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- delivery
- composition used
- relates
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111638123.4 | 2021-12-29 | ||
| CN202111638123 | 2021-12-29 | ||
| CN202210651178.7 | 2022-06-09 | ||
| CN202210651178 | 2022-06-09 | ||
| PCT/CN2022/143074 WO2023125738A1 (zh) | 2021-12-29 | 2022-12-29 | 用于递送的脂质和组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242974A1 true CA3242974A1 (en) | 2023-07-06 |
Family
ID=86998079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242974A Pending CA3242974A1 (en) | 2021-12-29 | 2022-12-29 | LIPID AND COMPOSITION USED FOR ADMINISTRATION |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250064750A1 (enExample) |
| EP (1) | EP4458806A4 (enExample) |
| JP (1) | JP2025501967A (enExample) |
| KR (1) | KR20240128984A (enExample) |
| CN (1) | CN120476106A (enExample) |
| AU (1) | AU2022424144A1 (enExample) |
| CA (1) | CA3242974A1 (enExample) |
| MX (1) | MX2024007242A (enExample) |
| TW (1) | TW202330458A (enExample) |
| WO (1) | WO2023125738A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023343844A1 (en) * | 2022-09-19 | 2025-04-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Method for preparing 2-hydroxyethyl aminocaproate compound and use thereof |
| AU2024307171A1 (en) | 2023-06-28 | 2026-01-15 | Shanghai Regenelead Therapies Co., Ltd. | Pharmaceutical composition containing cationic lipid and use thereof |
| WO2025103396A1 (zh) * | 2023-11-14 | 2025-05-22 | 上海瑞宏迪医药有限公司 | 一种含核酸构建体的药物组合物及其医药用途 |
| WO2025103414A1 (zh) * | 2023-11-14 | 2025-05-22 | 上海瑞宏迪医药有限公司 | 一种脂质纳米粒的制备方法和应用 |
| TW202532053A (zh) * | 2023-12-13 | 2025-08-16 | 大陸商上海瑞宏迪醫藥有限公司 | 用於遞送治療劑的組成物和化合物 |
| CN119019272A (zh) * | 2024-08-14 | 2024-11-26 | 中国药科大学 | 可电离脂质、包含其的组合物及其用途 |
| CN119191996A (zh) * | 2024-11-28 | 2024-12-27 | 浙江省质量科学研究院 | 一种双羟乙基氨基丙基羟乙基油胺的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| RS63986B1 (sr) * | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| BR112021021313A2 (pt) | 2019-04-25 | 2022-01-18 | Intellia Therapeutics Inc | Lipídios de amina ionizáveis e nanopartículas de lipídio |
| CN114763324A (zh) * | 2021-01-15 | 2022-07-19 | 纳肽得(青岛)生物医药有限公司 | 一种脂质化合物及脂质体与药物组合物 |
| CN113264842B (zh) * | 2021-07-21 | 2022-03-01 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| CN114773217B (zh) * | 2022-06-20 | 2022-10-18 | 深圳市瑞吉生物科技有限公司 | 用于递送核酸的阳离子脂质化合物和组合物及用途 |
-
2022
- 2022-12-29 AU AU2022424144A patent/AU2022424144A1/en active Pending
- 2022-12-29 TW TW111150722A patent/TW202330458A/zh unknown
- 2022-12-29 CN CN202280076308.7A patent/CN120476106A/zh active Pending
- 2022-12-29 WO PCT/CN2022/143074 patent/WO2023125738A1/zh not_active Ceased
- 2022-12-29 CA CA3242974A patent/CA3242974A1/en active Pending
- 2022-12-29 KR KR1020247025244A patent/KR20240128984A/ko active Pending
- 2022-12-29 MX MX2024007242A patent/MX2024007242A/es unknown
- 2022-12-29 JP JP2024539654A patent/JP2025501967A/ja active Pending
- 2022-12-29 US US18/725,552 patent/US20250064750A1/en active Pending
- 2022-12-29 EP EP22914988.5A patent/EP4458806A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007242A (es) | 2024-06-26 |
| JP2025501967A (ja) | 2025-01-24 |
| WO2023125738A1 (zh) | 2023-07-06 |
| TW202330458A (zh) | 2023-08-01 |
| CN120476106A (zh) | 2025-08-12 |
| EP4458806A4 (en) | 2025-04-30 |
| AU2022424144A1 (en) | 2024-08-08 |
| EP4458806A1 (en) | 2024-11-06 |
| US20250064750A1 (en) | 2025-02-27 |
| KR20240128984A (ko) | 2024-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51620B1 (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| MA58087B1 (fr) | Nouveaux dérivés de méthylquinazolinone | |
| MA58004B1 (fr) | Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux | |
| MA35833B1 (fr) | Dérivés de bétuline | |
| MA52948B1 (fr) | Composés | |
| MX2024008358A (es) | Medicina para tratar o prevenir el cancer. | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA50240A (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA31550B1 (fr) | Derives de 2,4,5-triphenyl imidazoline en tant qu'inhibiteurs de l'interaction entre les proteines p53 et mdm2, utilises en tant qu'agents anticancereux | |
| MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
| MA43251B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA56674B1 (fr) | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci | |
| MA42341A1 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| MA33420B1 (fr) | Dérivés fluorés de l'aminotriazole | |
| MA31596B1 (fr) | Nouveaux herbicides | |
| MA31741B1 (fr) | Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide | |
| MA31597B1 (fr) | Nouveaux herbicides | |
| CA2817362C (en) | Lipoyl compounds and their use for treating ischemic injury | |
| MA28269A1 (fr) | Arylpyrazoles substitués servant d'agents parasiticides | |
| MX2024007242A (es) | Lipido y composicion utilizada para la administracion. | |
| MA43400B1 (fr) | Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2 | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240703 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240703 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED Effective date: 20240703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240703 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241126 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241126 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251126 |